A Study of Real-world Outcomes Among Patients Treated With Ribociclib

Assessment of Real-world Outcomes Among Patients Treated With Kisqali (Ribociclib)

The main aim of the study was to evaluate the real-world tolerability and safety of ribociclib as a first-line (1L) treatment among adults with hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC).

This study used data from the Flatiron Health Research Database (FHRD). The FHRD is a longitudinal database derived from electronic health records (EHRs) and other real-world data (RWD) sources from cancer care providers across the United States. The dataset generated for this study included de-identified patient-level data for eligible individuals between 1 January 2015 up to the data cutoff date, 30 November 2022.

Inclusion criteria:

• Diagnosed with mBC on or after 1 January 2015.
• Had HR+/HER2- test results.
• Received ribociclib and endocrine therapy in 1L treatment.
• Patients had a gap of 90 days or less between mBC diagnosis date and the first structured EHR activity (e.g., lab tests and prescriptions) after metastatic diagnosis date.

Exclusion criteria:

None identified.